Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The NetherlandsYansi Wu, Gauthier Quinonez, Tom Belleman et al.|OSF Preprints (OSF Preprints)|2026Cited by 0